A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors.
Bevacizumab
Brain tumor
Irinotecan
Pediatric
Phase I
Temozolomide
Journal
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
ISSN: 1433-0350
Titre abrégé: Childs Nerv Syst
Pays: Germany
ID NLM: 8503227
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
26
11
2021
accepted:
26
02
2022
pubmed:
10
3
2022
medline:
28
4
2022
entrez:
9
3
2022
Statut:
ppublish
Résumé
Children with relapsed/refractory central nervous system (CNS) tumors require novel combinations of therapies. Irinotecan and temozolomide (IT) is a frequently used therapy with an established toxicity profile. Bevacizumab is an anti-VEGF monoclonal antibody with demonstrated activity in CNS tumors. Therefore, the combination of these agents has therapeutic potential in CNS tumors. The objective of this study was to determine the maximum tolerated dose (MTD) of escalating dose IT combined with a fixed dose of bevacizumab (BIT) in children with relapsed/refractory CNS tumors. A phase I trial was performed in a 3 + 3 design. Therapy toxicities and radiologic responses to treatment were described. One hundred eighty cycles of therapy were administered to 26 patients. The MTD of BIT was dose level 1, (bevacizumab 10 mg/kg on days 1 and 15, irinotecan 125 mg/m At the MTD, BIT therapy was well tolerated, and prolonged treatment courses of up to 24 cycles were feasible, with radiographic responses observed. Further evaluation is needed for efficacy in a phase II trial (NCT00876993, registered April 7, 2009, www. gov ).
Identifiants
pubmed: 35260913
doi: 10.1007/s00381-022-05479-7
pii: 10.1007/s00381-022-05479-7
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Irinotecan
7673326042
Dacarbazine
7GR28W0FJI
Camptothecin
XT3Z54Z28A
Temozolomide
YF1K15M17Y
Banques de données
ClinicalTrials.gov
['NCT00876993']
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
919-928Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2021) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol. https://doi.org/10.1093/neuonc/noab200
doi: 10.1093/neuonc/noab200
pubmed: 34608945
pmcid: 8804884
Johnston DL, Keene D, Strother D, Taneva M, Lafay-Cousin L, Fryer C, Scheinemann K, Carret AS, Fleming A, Afzal S, Wilson B, Bowes L, Zelcer S, Mpofu C, Silva M, Larouche V, Brossard J, Bouffet E (2018) Survival following tumor recurrence in children with medulloblastoma. J Pediatr Hematol Oncol. https://doi.org/10.1097/MPH.0000000000001095
doi: 10.1097/MPH.0000000000001095
pubmed: 29432312
Koschmann C, Bloom K, Upadhyaya S, Geyer JR, Leary SE (2016) Survival after relapse of medulloblastoma. J Pediatr Hematol Oncol. https://doi.org/10.1097/MPH.0000000000000547
doi: 10.1097/MPH.0000000000000547
pubmed: 26907655
Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. https://doi.org/10.1634/theoncologist.9-2-197
doi: 10.1634/theoncologist.9-2-197
pubmed: 15047924
Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, Bernstein M (2001) A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res. 7 (1): 32–37
Ma MK, Zamboni WC, Radomski KM, Furman WL, Santana VM, Houghton PJ, Hanna SK, Smith AK, Stewart CF (2000) Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res.6 (3): 813–819
Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, McLendon RE, Friedman AH, Tourt-Uhlig S, Miller LL, Friedman HS (2002) Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol. https://doi.org/10.1093/neuonc/4.2.109
doi: 10.1093/neuonc/4.2.109
pubmed: 11916501
pmcid: 1920653
Vassal G, Doz F, Frappaz D, Imadalou K, Sicard E, Santos A, O’Quigley J, Germa C, Risse ML, Mignard D, Pein F (2003) A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. https://doi.org/10.1200/JCO.2003.08.175
doi: 10.1200/JCO.2003.08.175
pubmed: 14551303
Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, Adamson PC, Blaney SM (2007) Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 25(29):4622-7.
Estlin EJ, Lashford L, Ablett S, Price L, Gowing R, Gholkar A, Kohler J, Lewis IJ, Morland B, Pinkerton CR, Stevens MC, Mott M, Stevens R, Newell DR, Walker D, Dicks-Mireaux C, McDowell H, Reidenberg P, Statkevich P, Marco A, Batra V, Dugan M, Pearson AD (1998) Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children’s Cancer Study Group. Br J Cancer. https://doi.org/10.1038/bjc.1998.555
doi: 10.1038/bjc.1998.555
Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children’s Oncology Group. Cancer. https://doi.org/10.1002/cncr.22961
doi: 10.1002/cncr.22961
pubmed: 17932894
Balmaceda C, Peereboom D, Pannullo S, Cheung YK, Fisher PG, Alavi J, Sisti M, Chen J, Fine RL (2008) Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer. https://doi.org/10.1002/cncr.23167
doi: 10.1002/cncr.23167
pubmed: 18246536
Barone G, Maurizi P, Tamburrini G, Riccardi R (2006) Role of temozolomide in pediatric brain tumors. Childs Nerv Syst. https://doi.org/10.1007/s00381-006-0081-z
doi: 10.1007/s00381-006-0081-z
pubmed: 16565851
Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S (2014) Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children’s Oncology Group Study. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.24874
doi: 10.1002/pbc.24874
pubmed: 24962521
pmcid: 4177031
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R (2017) Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol S1470–2045(17):30355–30358
DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP (2016) Phase I study of the Aurora A kinase inhibitor Alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. https://doi.org/10.1200/JCO.2015.65.4889
doi: 10.1200/JCO.2015.65.4889
pubmed: 27998223
pmcid: 4872349
Federico SM, Pappo AS, Sahr N, Sykes A, Campagne O, Stewart CF, Clay MR, Bahrami A, McCarville MB, Kaste SC, Santana VM, Helmig S, Gartrell J, Shelat A, Brennan RC, Hawkins D, Godwin K, Bishop MW, Furman WL, Stewart E (2020) A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer S0959–8049(20):30347–30356
Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722-9
Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ, Children’s Oncology Group Study (2008) Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. https://doi.org/10.1200/JCO.2007.11.9230
doi: 10.1200/JCO.2007.11.9230
Gururangan S, Fangusaro J, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Gajjar A, Goldman S, Friedman HS, Packer RJ, Boyett JM, Kun LE, McLendon R (2012) Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma–a Pediatric Brain Tumor Consortium study. Neuro Oncol. https://doi.org/10.1093/neuonc/nos213
doi: 10.1093/neuonc/nos213
pubmed: 23019233
pmcid: 3480265
van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A (2018) Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncol S1470–2045(18):30362
Glade Bender J, Yamashiro DJ, Fox E (2011) Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist. https://doi.org/10.1634/theoncologist.2011-0148
doi: 10.1634/theoncologist.2011-0148
pubmed: 22042784
pmcid: 3233297
Venkatramani R, Malogolowkin M, Davidson TB, May W, Sposto R, Mascarenhas L (2013) A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors. PLoS One. https://doi.org/10.1371/journal.pone.0068416
doi: 10.1371/journal.pone.0068416
pubmed: 23894304
pmcid: 3718768
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. https://doi.org/10.1200/JCO.2008.19.8721
doi: 10.1200/JCO.2008.19.8721
pubmed: 19720927
pmcid: 4979079
Levy AS, Krailo M, Chi S, Villaluna D, Springer L, Williams-Hughes C, Fouladi M, Gajjar A (2021) Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.29031
doi: 10.1002/pbc.29031
pubmed: 34913590
Crotty EE, Leary SES, Geyer JR, Olson JM, Millard NE, Sato AA, Ermoian RP, Cole BL, Lockwood CM, Paulson VA, Browd SR, Ellenbogen RG, Hauptman JS, Lee A, Ojemann JG, Vitanza NA (2020) Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children’s Hospital experience. J Neurooncol. https://doi.org/10.1007/s11060-020-03558-w
doi: 10.1007/s11060-020-03558-w
pubmed: 32556862
Schiavetti A, Varrasso G, Mollace MG, Dominici C, Ferrara E, Papoff P, Di Biasi C (2019) Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience. Childs Nerv Syst. https://doi.org/10.1007/s00381-019-04117-z
doi: 10.1007/s00381-019-04117-z
pubmed: 30903281
Modak S, Kushner BH, Basu E, Roberts SS, Cheung NK (2017) Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: results of a phase II study. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.26448
doi: 10.1002/pbc.26448
pubmed: 28409892
pmcid: 5555116
Hummel TR, Salloum R, Drissi R, Kumar S, Sobo M, Goldman S, Pai A, Leach J, Lane A, Pruitt D, Sutton M, Chow LM, Grimme L, Doughman R, Backus L, Miles L, Stevenson C, Fouladi M, DeWire M (2016) A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. J Neurooncol. https://doi.org/10.1007/s11060-015-2008-6
doi: 10.1007/s11060-015-2008-6
pubmed: 27350411
pmcid: 5288808
Zaky W, Wellner M, Brown RJ, Bluml S, Finlay JL, Dhall G (2013) Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab. Pediatr Hematol Oncol. https://doi.org/10.3109/08880018.2013.829895
doi: 10.3109/08880018.2013.829895
pubmed: 24050762
Aguilera D, Mazewski C, Fangusaro J, MacDonald TJ, McNall-Knapp RY, Hayes LL, Kim S, Castellino RC (2013) Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Childs Nerv Syst. https://doi.org/10.1007/s00381-012-2013-4
doi: 10.1007/s00381-012-2013-4
pubmed: 23296323
pmcid: 3963487
Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J (2013) Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.24547
doi: 10.1002/pbc.24547
pubmed: 24376097
pmcid: 3989390
Tsakatikas S, Papageorgiou G, Fioretzaki R, Kosmas C (2021) An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors. Crit Rev Oncol Hematol S1040–8428(21):00244–00254
Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. https://doi.org/10.1001/jama.2008.656
doi: 10.1001/jama.2008.656
pubmed: 19017914
Li LJ, Chen DF, Wu GF, Guan WJ, Zhu Z, Liu YQ, Gao GY, Qin YY, Zhong NS (2018) Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma. J Thorac Dis. https://doi.org/10.21037/jtd.2018.07.09
Fangusaro J, Gururangan S, Poussaint TY, McLendon RE, Onar-Thomas A, Warren KE, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Kun LE, Fouladi M (2013) Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer. https://doi.org/10.1002/cncr.28343
doi: 10.1002/cncr.28343
pubmed: 24104527
Papageorgiou GI, Tsakatikas SA, Fioretzaki RG, Kosmas C (2021) Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab. Anticancer Drugs. https://doi.org/10.1097/CAD.0000000000001021
doi: 10.1097/CAD.0000000000001021
pubmed: 34232951